Compare · MOVE vs SLNO
MOVE vs SLNO
Side-by-side comparison of Corvex Inc. (MOVE) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOVE and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 83.5x MOVE ($33.1M).
- Over the past year, MOVE is up 209.5% and SLNO is down 33.6% - MOVE leads by 243.1 points.
- SLNO has been more active in the news (39 items in the past 4 weeks vs 8 for MOVE).
- SLNO has more recent analyst coverage (12 ratings vs 0 for MOVE).
- Company
- Corvex Inc.
- Soleno Therapeutics Inc.
- Price
- $17.11-3.11%
- $53.02+0.08%
- Market cap
- $33.1M
- $2.76B
- 1M return
- +21.73%
- +0.76%
- 1Y return
- +209.49%
- -33.64%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 8
- 39
- Recent ratings
- 0
- 12
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest MOVE
- Semiconductor and Computing Veteran Nicholas Donofrio to Join Corvex Board of Directors as the Company Scales Secure AI Infrastructure and Prepares to Launch Token Factory
- SEC Form DEF 14A filed by Corvex Inc.
- SEC Form PRER14A filed by Corvex Inc.
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Corvex Reports Q1 2026 Financial Results and Provides Business Update
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Corvex Inc.
- SEC Form NT 10-Q filed by Corvex Inc.
- Corvex to Host First Quarter 2026 Earnings Call on Tuesday, May 19, 2026
- Corvex Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)